News | July 06, 2024
Dabur India updates on Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
WINREVAIR is a breakthrough biologic for this rare, progressive disease
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Connecting new production and consumption areas of chilled food by low-carbon transportation services
Ayush is expanding beyond wellness to therapeutic wellness
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
Subscribe To Our Newsletter & Stay Updated
